Appili Therapeutics Inc
- LAST PRICE0.0400
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0350/ 257
- Ask / Lots0.0400/ 58
- Open / Previous Close0.0400 / 0.0400
- Day Range
- 52 Week Range
- Volume113,800
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | APLI |
|---|---|---|
| 10:22 ET | 5000 | 0.04 |
| 02:21 ET | 27000 | 0.04 |
| 03:01 ET | 79000 | 0.04 |
| 03:03 ET | 1000 | 0.04 |
| 03:15 ET | 1000 | 0.04 |
Today
Yesterday
Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders, from 8:30AM ET on Thursday Nov 07, 2024 by Dow Jones
8:30AM ET on Thursday Nov 07, 2024 by Dow JonesPress Release: Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders, from 8:30AM ET on Thursday Nov 07, 2024 by Dow Jones
8:30AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 6, 2024
Appili Therapeutics Announces Results of Special Meeting of Shareholders, from 5:55PM ET on Wednesday Nov 06, 2024 by Dow Jones
5:55PM ET on Wednesday Nov 06, 2024 by Dow JonesPress Release: Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem, from 8:30AM ET on Wednesday Nov 06, 2024 by Dow Jones
8:30AM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Appili Therapeutics Inc | 4.9M | -1.3x | --- |
Innovotech Inc | 5.9M | -16.0x | --- |
Principal Technologies Inc | 6.3M | -2.2x | --- |
Awakn Life Sciences Corp | 4.6M | -1.2x | --- |
Quest Pharmatech Inc | 5.1M | 0.4x | --- |
Asep Medical Holdings Inc | 4.5M | -0.8x | --- |
Company Information
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701 and ATI-1801. LIKMEZ (ATI-1501) is its advanced commercial stage asset, a liquid oral reformulation of the antibiotic metronidazole to treat serious anaerobic and protozoal infections. ATI-1701 is a live-attenuated vaccine for Francisella tularensis (F. tularensis), the bacterium which causes tularemia. ATI-1801 is a topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis.
Contact Information
- Headquarters
- #21-1344 Summer StreetHALIFAX, NS, Canada B3H 0A8
- Phone
- 902-442-4655
- Fax
- 902-442-4655
Executives
- Chairman of the Board
- Armand Balboni
- President, Chief Executive Officer, Director
- Don Cilla
- Acting Chief Financial Officer
- Kenneth Howling
- Director - New Product Development
- Arthur Baran
- Director - Non-Clinical Research
- Carl Gelhaus
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.9M |
|---|---|
Revenue (TTM) | $827.4K |
Shares Outstanding | 121.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.97 |
EPS | $-0.03 |
Book Value | $-0.09 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | 5.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,039.87% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
